Compare Repligen Corporation Common Stock (RGEN) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs J M Smucker Co — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while J M Smucker Co trades at $121.85 (market cap $12.96B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.69% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and J M Smucker Co for 74 Days on average.
| RGEN | SJM | |
|---|---|---|
Market Cap | $11.14B | $12.96B |
Volume | 1,259,263 | 1,039,289 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $132.34 |
52-Week Low | $102.87 | $89.53 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $11.02B | $19.81B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SJM trades at $121.84, up 1.52% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.24, beating expectations, and raised FY27 guidance. However, 2025 fundamentals show a net loss of $1.23B and elevated P/E of 56.7, while analyst consensus is a Buy with a $138.23 price target.
Outlook is mixed; robust growth in segments like Uncrustables and raised guidance support upside, but high valuation, volatile profitability, and debt levels pose risks. The stock offers a dividend yield but faces competitive and margin pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
